Abstract
Expression of the p53 gene protects cells against malignant transformation1,2. Whereas control of p53 degradation has been a subject of intense scrutiny, little is known about the factors that regulate p53 synthesis1,2. Here we show that p53 messenger RNA levels are low in a large proportion of breast tumours. Seeking potential regulators of p53 transcription, we found consensus HOX binding sites3,4 in the p53 promoter5. Transient transfection of Hox/HOXA5 activated the p53 promoter. Expression of HOXA5 in epithelial cancer cells expressing wild-type p53, but not in isogenic variants lacking the p53 gene6, led to apoptotic cell death. Moreover, breast cancer cell lines and patient tumours display a coordinate loss of p53 and HOXA5 mRNA and protein expression. The HOXA5 promoter region was methylated in 16 out of 20 p53-negative breast tumour specimens. We conclude that loss of expression of p53 in human breast cancer may be primarily due to lack of expression of HOXA5.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Prives, C. & Hall, P. A. The p53 pathway. J. Pathol. 187, 112–126 ( 1999).
Reisman, D. & Loging, W. T. Transcriptional regulation of the p53 tumor suppressor gene. Semin. Cancer Biol. 8, 317–324 (1998).
Pellerin, I., Schnabel, C., Catron, K. M. & Abate, C. Hox proteins have different affinities for a consensus DNA site that correlate with the positions of their genes on the hox cluster. Mol. Cell. Biol. 14, 4532–4545 ( 1994).
Zhao, J. J., Lazzarini, R. A. & Pick, L. Functional dissection of the mouse Hox-a5 gene. EMBO J. 15, 1313–1322 ( 1996).
Reisman, D., Greenberg, M. & Rotter, V. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc. Natl Acad. Sci. USA 85, 5146–5150 (1988).
Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501 (1998).
Pharoah, P. D. P., Day, N. E. & Caldas, C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Brit. J. Cancer 80, 1968–1973 (1999).
Deschamps, J. & Meijlink, F. Mammalian homeobox genes in normal development and neoplasia. Crit. Rev. Oncog. 3, 117–173 (1992).
Scott, M. P. Hox genes, arms and the man. Nature Genet. 15, 117–118 (1997).
Cillo, C. et al. Hox gene expression in normal and neoplastic human kidney. Int. J. Cancer 51, 892–897 (1992).
De Vita, G. et al. Expression of homeobox-containing genes in primary and metastatic colorectal cancer. Eur. J. Cancer 6, 887 –893 (1993).
Care, A. et al. HOXB7 constitutively activates fibroblast growth factor in melanomas. Mol. Cell. Biol. 16, 4842– 4851 (1996).
Chariot, A., & Castronovo, V. Detection of HOXA1 expression in human breast cancer. Biochem. Biophys. Res. Commun. 222, 292-297 (1996).
Cillo, C., Faiella, A., Cantile, M. & Boncinelli, E. Homeobox genes and cancer. Exp. Cell. Res. 248, 1– 9 (1999).
Snedecor G. W. & Cochran, W. G. Statistical Methods (Iowa State Univ. Press, Ames, 1982).
Li, F. et al. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J. Biol. Chem. 272, 30299–30305 (1997).
Larochelle, C., Tremblay, M., Bernier, D., Aubin, J. & Jeanotte, L. Multiple cis-acting regions are required for restricted spatio-temporal Hoxa5 gene expression. Dev. Dyn. 214, 127–140 ( 1999).
Aubin, J., Lemieux, M., Tremblay, M., Behringer, R. R. & Jeanotte, L. Transcriptional interferences at the Hoxa4/Hoxa5 locus: importance of correct Hoxa5 expression for proper specification of the axial skeletal. Dev. Dyn. 212, 141 –156 (1999).
Hanson, R. D. et al. Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proc. Natl Acad. Sci. USA 96, 14372–14377 (1999).
Bird, A. P. & Wolffe, A. P. Methylation-induced repression–belts, braces, and chromatin. Cell 99, 451– 454 (1999).
Herman J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. 93, 9821–9826 ( 1996).
Runnebaum, I. B., Nagarajan, M., Bowman, M., Soto, D. & Sukumar, S. Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl Acad. Sci USA 88, 10657–10661 (1991).
Glebov, O. K., Mc Kenzie, K. E., White, C. A. & Sukumar, S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res. 54, 3703–3709 (1994).
Bates, S. A. V. & Vousden, K. H. Mechanisms of p53-mediated apoptosis. Cell. Mol. Life Sci. 55, 28–37 (1999).
Venkatachalam, S. et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657–4667 ( 1998).
Gottleib, E. et al. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age and tissue dependent changes in radiaton-induced activation during embryogenesis. EMBO J. 16, 1381– 1390 (1997).
Seed B. & Sheen, J. Y. A simple phase extraction assay for chloramphenicol acetyltransferase activity. Gene 67, 271–277 (1988).
Raman, V., Andrews, M. E., Harkey, M. A. & Raff, R. A. Protein–DNA interactions at putative regulatory regions of two coordinately expressed genes, msp130 and PM27, during skeletogenesis in sea urchin embryos. Int. J. Dev. Biol. 37, 499– 507 (1993).
Acknowledgements
This work was supported by grants from the USPHS, the Susan G. Komen Foundation, the Department of Defense and the Breast Cancer Research Foundation to S.S. We thank A. Rein and B. Vogelstein for discussions and for critically reviewing the manuscript, V. Band for generously sharing data and reagents, and D. Korz for expert technical assistance.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Raman, V., Martensen, S., Reisman, D. et al. Compromised HOXA5 function can limit p53 expression in human breast tumours . Nature 405, 974–978 (2000). https://doi.org/10.1038/35016125
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35016125
This article is cited by
-
Deregulation of miR-375 Inhibits HOXA5 and Promotes Migration, Invasion, and Cell Proliferation in Breast Cancer
Applied Biochemistry and Biotechnology (2023)
-
HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme
BMC Cancer (2022)
-
Prognostic significance of KLF4 in solid tumours: an updated meta-analysis
BMC Cancer (2022)
-
Molecular implications of HOX genes targeting multiple signaling pathways in cancer
Cell Biology and Toxicology (2022)
-
HOXA5 counteracts the function of pathological scar-derived fibroblasts by partially activating p53 signaling
Cell Death & Disease (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.